Research progress in metformin for treatment of prostate cancer

LUO Hengfeng; YANG Xukai; CHEN Yajie; YUAN Yacheng; QIU Xiaolong; NING Yiping

doi:10.7619/jcmp.20231475

Journal of Clinical Medicine in Practice > 2023 > 27(20): 142-148. > DOI: 10.7619/jcmp.20231475

LUO Hengfeng, YANG Xukai, CHEN Yajie, YUAN Yacheng, QIU Xiaolong, NING Yiping. Research progress in metformin for treatment of prostate cancer[J]. Journal of Clinical Medicine in Practice, 2023, 27(20): 142-148. DOI: 10.7619/jcmp.20231475

Citation:

PDF (795 KB)

Research progress in metformin for treatment of prostate cancer

LUO Hengfeng^{1, 2},
YANG Xukai^1, ,,
CHEN Yajie^{1, 2},
YUAN Yacheng^{1, 2},
QIU Xiaolong^{1, 2},
NING Yiping^{1, 2}

1.
Department of Urinary Surgery, the 940 th Hospital of Joint Logistics Support Force of the ChinesePeople's Liberation Army, Lanzhou, Gansu, 730000
2.
the First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou, Gansu, 730000

More Information

Received Date: May 07, 2023
Revised Date: September 05, 2023
Available Online: November 05, 2023

Graphical Abstract

Abstract

Abstract

After treating by androgen deprivation therapy (ADT) in patients with prostate cancer, the prostate cancer cells gradually adapt to low androgen environments, and condition of disease will inevitably evolve to castration resistant prostate cancer (CRPC). In recent years, studies have found that single or combined treatment with metformin (MF) may delay the development of prostate cancer in the middle-aged and elderly patients. This paper aimed to take a brief review of the research progress on the effect of MF on prostate cancer.
- prostate cancer,
- metformin,
- androgen deprivation therapy,
- low androgen

FullText(HTML)

References (62)

References

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
[3]	XIA C F, DONG X S, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J, 2022, 135(5): 584-590. doi: 10.1097/CM9.0000000000002108
[4]	MORETTI T B C, REIS L O. The natural history of evidence on radical prostatectomy: what have 20 years of robots given us[J]. Eur Urol Focus, 2022, 8(6): 1859-1860. doi: 10.1016/j.euf.2022.06.006
[5]	MANSINHO A, MACEDO D, FERNANDES I, et al. Castration-resistant prostate cancer: mechanisms, targets and treatment[J]. Adv Exp Med Biol, 2018, 1096: 117-133.
[6]	MARCHIONI M, MARANDINO L, AMPARORE D, et al. Factors influencing survival in metastatic castration-resistant prostate cancer therapy[J]. Expert Rev Anticancer Ther, 2022, 22(10): 1061-1079. doi: 10.1080/14737140.2022.2114458
[7]	ROVIELLO G, CATALANO M, OTTANELLI C, et al. Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice[J]. Med Oncol, 2022, 39(10): 145. doi: 10.1007/s12032-022-01739-3
[8]	陈丹, 董婧颖, 耿瑞蔓, 等. 二甲双胍抑制前列腺癌细胞的增殖、迁移、侵袭及其机制[J]. 华西药学杂志, 2022, 37(2): 159-162. https://www.cnki.com.cn/Article/CJFDTOTAL-HXYO202202012.htm
[9]	白培德, 张文炤, 谢顺强, 等. 二甲双胍通过调节PKM2调控肿瘤细胞增殖与凋亡影响前列腺癌浸润和转移的机制研究[J]. 临床泌尿外科杂志, 2022, 37(11): 846-852. https://www.cnki.com.cn/Article/CJFDTOTAL-LCMW202211009.htm
[10]	HAYASHI T, FUJITA K, MATSUSHITA M, et al. Metformin inhibits prostate cancer growth induced by a high-fat diet in Pten-deficient model mice[J]. Int J Urol, 2019, 26(2): 307-309. doi: 10.1111/iju.13847
[11]	OLOKPA E, MANDAPE S N, PRATAP S, et al. Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells[J]. BMC Cancer, 2022, 22(1): 1025. doi: 10.1186/s12885-022-10115-3
[12]	YANG B, DAMODARAN S, KHEMEES T A, et al. Synthetic lethal metabolic targeting of androgen-deprived prostate cancer cells with metformin[J]. Mol Cancer Ther, 2020, 19(11): 2278-2287. doi: 10.1158/1535-7163.MCT-19-1141
[13]	LEE S Y, SONG C H, XIE Y B, et al. SMILE upregulated by metformin inhibits the function of androgen receptor in prostate cancer cells[J]. Cancer Lett, 2014, 354(2): 390-397. doi: 10.1016/j.canlet.2014.09.001
[14]	WANG Y, LIU G L, TONG D L, et al. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor[J]. Prostate, 2015, 75(11): 1187-1196. doi: 10.1002/pros.23000
[15]	LIU Q L, TONG D L, LIU G L, et al. Metformin inhibits prostate cancer progression by targeting tumor-associated inflammatory infiltration[J]. Clin Cancer Res, 2018, 24(22): 5622-5634. doi: 10.1158/1078-0432.CCR-18-0420
[16]	CHEN D, CHOU F J, CHEN Y, et al. Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity[J]. Cancer Lett, 2020, 495: 100-111. doi: 10.1016/j.canlet.2020.07.040
[17]	CHEN X W, LI C L, HE T T, et al. Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression[J]. Cancer Biol Ther, 2016, 17(5): 507-514. doi: 10.1080/15384047.2016.1156273
[18]	ENGERS R, ZIEGLER S, MUELLER M, et al. Prognostic relevance of increased Rac GTPase expression in prostate carcinomas[J]. Endocr Relat Cancer, 2007, 14(2): 245-256. doi: 10.1677/ERC-06-0036
[19]	DIRAT B, ADER I, GOLZIO M, et al. Inhibition of the GTPase Rac1 mediates the antimigratory effects of metformin in prostate cancer cells[J]. Mol Cancer Ther, 2015, 14(2): 586-596. doi: 10.1158/1535-7163.MCT-14-0102
[20]	KATO H, SEKINE Y, FURUYA Y, et al. Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor[J]. Biochem Biophys Res Commun, 2015, 461(1): 115-121. doi: 10.1016/j.bbrc.2015.03.178
[21]	BEN SAHRA I, LAURENT K, LOUBAT A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level[J]. Oncogene, 2008, 27(25): 3576-3586. doi: 10.1038/sj.onc.1211024
[22]	MANFIOLETTI G, FEDELE M. Epithelial-mesenchymal transition (EMT) 2021[J]. Int J Mol Sci, 2022, 23(10): 5848. doi: 10.3390/ijms23105848
[23]	ZHANG J, SHEN C W, WANG L, et al. Metformin inhibits epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4[J]. Biochem Biophys Res Commun, 2014, 452(3): 746-752. doi: 10.1016/j.bbrc.2014.08.154
[24]	WANG J Z, ZHU W, HAN J, et al. The role of the HIF-1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer[J]. Cancer Commun, 2021, 41(7): 560-575. doi: 10.1002/cac2.12158
[25]	YU T, YANG G, HOU Y, et al. Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance[J]. Oncogene, 2017, 36(15): 2131-2145. doi: 10.1038/onc.2016.370
[26]	HARDIE D G, ROSS F A, HAWLEY S A. AMPK: a nutrient and energy sensor that maintains energy homeostasis[J]. Nat Rev Mol Cell Biol, 2012, 13(4): 251-262.
[27]	LUO M, TAN X Y, MU L, et al. MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway[J]. Sci Rep, 2017, 7: 43427. doi: 10.1038/srep43427
[28]	LEE Y H A, ZHOU J D, HUI J M H, et al. Risk of new-onset prostate cancer for metformin versus sulfonylurea use in type 2 diabetes mellitus: a propensity score-matched study[J]. J Natl Compr Canc Netw, 2022, 20(6): 674-682, e15. doi: 10.6004/jnccn.2022.7010
[29]	KOO H Y, JEONG S M, CHO M H, et al. Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality[J]. Sci Rep, 2021, 11(1): 16171. doi: 10.1038/s41598-021-95764-3
[30]	NAIR-SHALLIKER V, BANG A, EGGER S, et al. Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study[J]. Br J Cancer, 2022, 127(4): 735-746. doi: 10.1038/s41416-022-01827-1
[31]	KUO Y J, SUNG F C, HSIEH P F, et al. Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: a nationwide population-based cohort study[J]. Cancer Med, 2019, 8(5): 2514-2523. doi: 10.1002/cam4.2025
[32]	JO J K, SONG H K, HEO Y, et al. Risk analysis of metformin use in prostate cancer: a national population-based study[J]. Aging Male, 2023, 26(1): 2156497. doi: 10.1080/13685538.2022.2156497
[33]	GOLDBERG H, MOHSIN F K, BERLIN A, et al. The suggested chemopreventive association of metformin with prostate cancer in diabetic patients[J]. Urol Oncol, 2021, 39(3): 191. e17-191. 191, e24. doi: 10.1016/j.urolonc.2020.08.032
[34]	FREEDMAN L S, AGAY N, FARMER R, et al. Metformin treatment among men with diabetes and the risk of prostate cancer: a population-based historical cohort study[J]. Am J Epidemiol, 2022, 191(4): 626-635. doi: 10.1093/aje/kwab287
[35]	WANG Y B, LIU X X, YAN P F, et al. Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies[J]. Eur J Cancer Prev, 2020, 29(1): 42-52. doi: 10.1097/CEJ.0000000000000514
[36]	LEE Y H A, HUI J M H, CHAN J S K, et al. Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: a population-based study[J]. Prostate, 2023, 83(1): 119-127. doi: 10.1002/pros.24443
[37]	KHAN S, CHANG S H, HICKS V, et al. Improved survival with post-diagnostic metformin and statin use in a racially diverse cohort of US Veterans with advanced prostate cancer[J]. Prostate Cancer Prostatic Dis, 2022, 25(4): 707-712. doi: 10.1038/s41391-021-00475-5
[38]	HUYNH L M, KEIT E, HUANG E, et al. Protective effects of metformin against biochemical failure following radical prostatectomy or radiation therapy in localized prostate cancer[J]. Urology, 2021, 155: 172-178. doi: 10.1016/j.urology.2021.01.030
[39]	ABOELNAGA E M, ABOELNAGA M M, ELKALLA H M. Metformin addition to androgen deprivation therapy effect on cancer prostate patients with type 2 diabetes[J]. Diabetes Metab Syndr, 2021, 15(5): 102251. doi: 10.1016/j.dsx.2021.102251
[40]	YAO X Y, LIU H R, XU H. The impact of metformin use with survival outcomes in urologic cancers: a systematic review and meta-analysis[J]. Biomed Res Int, 2021, 2021: 5311828.
[41]	TAUSSKY D, PREISSER F, KARAKIEWICZ P I, et al. Impact of diabetes and metformin use on prostate cancer outcome of patients treated with radiation therapy: results from a large institutional database[J]. Can J Urol, 2018, 25(5): 9509-9515.
[42]	HE K C, HU H T, YE S L, et al. The effect of metformin therapy on incidence and prognosis in prostate cancer: a systematic review and meta-analysis[J]. Sci Rep, 2019, 9(1): 2218. doi: 10.1038/s41598-018-38285-w
[43]	LINKEVICIUTE-ULINSKIENE D, PATASIUS A, KINCIUS M, et al. Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer[J]. Scand J Urol, 2020, 54(5): 401-407. doi: 10.1080/21681805.2020.1798502
[44]	YANG J, YANG H, CAO L, et al. Prognostic value of metformin in cancers: an updated meta-analysis based on 80 cohort studies[J]. Medicine, 2022, 101(49): e31799. doi: 10.1097/MD.0000000000031799
[45]	ALGHANDOUR R, EBRAHIM M A, ELSHAL A M, et al. Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED)[J]. Urol Oncol, 2021, 39(12): 831. e1-831. e10. doi: 10.1016/j.urolonc.2021.05.020
[46]	KIM J O, MCDONALD M O, ONG A, et al. Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase Ⅱ randomized controlled trial[J]. Radiat Oncol, 2021, 16(1): 212. doi: 10.1186/s13014-021-01935-x
[47]	RICHARDS K A, LIOU J I, CRYNS V L, et al. Metformin use is associated with improved survival for patients with advanced prostate cancer on androgen deprivation therapy[J]. J Urol, 2018, 200(6): 1256-1263. doi: 10.1016/j.juro.2018.06.031
[48]	MARK M, KLINGBIEL D, MEY U, et al. Impact of addition of metformin to abiraterone in metastatic castration-resistant prostate cancer patients with disease progressing while receiving abiraterone treatment (MetAb-pro): phase 2 pilot study[J]. Clin Genitourin Cancer, 2019, 17(2): e323-e328. doi: 10.1016/j.clgc.2018.12.009
[49]	KHAN S, CAI J W, NIELSEN M E, et al. The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study[J]. Cancer Causes Control, 2018, 29(11): 1143-1150. doi: 10.1007/s10552-018-1087-z
[50]	WANG C P, LEHMAN D M, LAM Y F, et al. Metformin for reducing racial/ethnic difference in prostate cancer incidence for men with type Ⅱ diabetes[J]. Cancer Prev Res, 2016, 9(10): 779-787. doi: 10.1158/1940-6207.CAPR-15-0425
[51]	JIMÉNEZ-VACAS J M, HERRERO-AGUAYO V, MONTERO-HIDALGO A J, et al. Clinical, cellular, and molecular evidence of the additive antitumor effects of biguanides and statins in prostate cancer[J]. J Clin Endocrinol Metab, 2021, 106(2): e696-e710. doi: 10.1210/clinem/dgaa877
[52]	RAFFAELE M, PITTALÁV, ZINGALES V, et al. Heme oxygenase-1 inhibition sensitizes human prostate cancer cells towards glucose deprivation and metformin-mediated cell death[J]. Int J Mol Sci, 2019, 20(10): 2593. doi: 10.3390/ijms20102593
[53]	TRAN L N K, KICHENADASSE G, MOREL K L, et al. The combination of metformin and valproic acid has a greater anti-tumoral effect on prostate cancer growth in vivo than either drug alone[J]. In Vivo, 2019, 33(1): 99-108. doi: 10.21873/invivo.11445
[54]	SUN S B, GONG F E, LIU P, et al. Metformin combined with quercetin synergistically repressed prostate cancer cells via inhibition of VEGF/PI3K/Akt signaling pathway[J]. Gene, 2018, 664: 50-57. doi: 10.1016/j.gene.2018.04.045
[55]	QIU J, YANG T H, LONG Y L, et al. Mitochondrial respiration inhibitor enhances the anti-tumor effect of high-dose ascorbic acid in castration-resistant prostate cancer[J]. J Mol Med, 2023, 101(1/2): 125-138.
[56]	LOPEZ D S, MALAGARIS I, POLYCHRONOPOULOU E, et al. Metformin and testosterone replacement therapy inversely associated with hormone-associated cancers (prostate, colorectal and male breast cancers) among older White and Black men[J]. Clin Endocrinol, 2022, 97(6): 792-803. doi: 10.1111/cen.14803
[57]	KONG Y F, ZHANG Y Q, MAO F Y, et al. Inhibition of EZH2 enhances the antitumor efficacy of metformin in prostate cancer[J]. Mol Cancer Ther, 2020, 19(12): 2490-2501. doi: 10.1158/1535-7163.MCT-19-0874
[58]	ESLAMI S S, JAFARI D, MONTAZERI H, et al. Combination of curcumin and metformin inhibits cell growth and induces apoptosis without affecting the cell cycle in LNCaP prostate cancer cell line[J]. Nutr Cancer, 2021, 73(6): 1026-1039. doi: 10.1080/01635581.2020.1783327
[59]	KOROGLU AYDIN P, KARABULUT-BULAN O, BUGAN I, et al. The protective effect of metformin against testicular damage in diabetes and prostate cancer model[J]. Cell Biochem Funct, 2022, 40(1): 60-70. doi: 10.1002/cbf.3674
[60]	KOROGLU-AYDIN P, BAYRAK B B, BUGAN I, et al. Histological and biochemical investigation of the renoprotective effects of metformin in diabetic and prostate cancer model[J]. Toxicol Mech Methods, 2021, 31(7): 489-500. doi: 10.1080/15376516.2021.1919810
[61]	BAYRAK B B, KOROGLU P, KARABULUT BULAN O, et al. Metformin protects against diabetes-induced heart injury and dunning prostate cancer model[J]. Hum Exp Toxicol, 2021, 40(2): 297-309. doi: 10.1177/0960327120947452
[62]	OZEL A B, DAGSUYU E, AYDIN P K, et al. Brain boron level, DNA content, and myeloperoxidase activity of metformin-treated rats in diabetes and prostate cancer model[J]. Biol Trace Elem Res, 2022, 200(3): 1164-1170. doi: 10.1007/s12011-021-02708-z

Cited By

Cited by

Periodical cited type(2)

1.	李烁烁，李清扬，周忠涛，白怀毓，张静. 人工智能在COPD病人延续性护理中的应用进展. 循证护理. 2024(14): 2535-2539 .
2.	文玉婵，黄勇. 远程医疗在慢性阻塞性肺疾病患者呼吸康复管理中的应用. 重庆医学. 2023(02): 283-287 .

Other cited types(0)

Get Citation

PDF

XML

Article views (155) PDF downloads (21) Cited by(2)

Turn off MathJax

Article Contents

Abstract

References

Research progress in metformin for treatment of prostate cancer

Abstract

References

Cited by

Periodical cited type(2)

Other cited types(0)

Catalog

Export File

Citation

Format

Content